Oxiris膜细胞因子血液吸附与标准治疗在心脏手术中的随机对照试验
法国单中心随机试验纳入70例择期心脏手术且预期体外循环时间超过90分钟的患者,比较Oxiris膜血液吸附与标准治疗。主要终点术后第1天微血管血流指数组间差异为-0.17(95%CI -0.44至0.10,P=0.2),30天复合不良结局两组分别为42%与35%(P=0.7),细胞因子和血管生成素变化无显著差异。
要点
- 心脏手术体外循环时间超过90分钟的高炎症风险患者中,Oxiris膜血液吸附未改善术后第1天微循环。
- 30天复合不良结局在Oxiris组与标准组间无显著差异(42% vs 35%,P=0.7)。
- 细胞因子和血管生成素的整体变化两组间无显著差异。
核心结论
- 在择期心脏手术且体外循环时间延长的患者中,未能证明Oxiris膜血液吸附对微循环和主要心血管事件有益。
研究设计与样本
- 法国Amiens大学医院单中心随机对照试验,纳入70例择期心脏手术且预期体外循环时间超过90分钟的成人患者。
- 患者随机分配至标准组或Oxiris组,Oxiris组在Prismaflex装置上以450 ml/min血流速率于体外循环期间使用Oxiris膜。
- 主要终点为术后第1天舌下微循环微血管血流指数(0-3分),次要终点为术后30天内复合不良结局,并进行意向性治疗分析。
主要发现
- 术后第1天微血管血流指数组间差异(Oxiris减标准)为-0.17(95%CI -0.44至0.10),P=0.2。
- 30天复合不良结局发生率Oxiris组为42%(14例),标准组为35%(12例),P=0.7。
- 细胞因子和血管生成素的整体变化两组间无显著差异。
临床怎么用
- 对于体外循环时间延长的择期心脏手术患者,不支持常规使用Oxiris膜血液吸附以改善微循环或降低主要心血管事件。
局限性
- 单中心研究,样本量70例,可能不足以检测微小差异。
- Oxiris组有2例被排除(1例未手术,1例在深低温下手术),可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac surgery can lead to dysregulation with a proinflammatory state, resulting in adverse outcomes. Hemadsorption using the AN-69 membrane (Oxiris membrane, Baxter, USA) has the properties to chelate inflammatory cytokines. The authors hypothesized that in patients at high risk of inflammation, the use of the Oxiris membrane could decrease inflammation, preserve endothelial function, and improve postoperative outcomes. METHODS: The authors conducted a randomized single-center study at Amiens University Hospital (Amiens, France). The study population consisted of adult patients admitted for scheduled cardiac surgery with an expected cardiopulmonary bypass (CPB) time greater than 90 min. The patients were allocated to either the standard group or the Oxiris group. The intervention consisted of using the Oxiris membrane on a Prismaflex device (Baxter, USA) at a blood flow rate of 450 ml/min during CPB. The primary outcome was the assessment of microcirculation on day 1 after surgery by measuring sublingual microcirculation using the microvascular flow index. Microvascular flow index reflects the microcirculation flow type and is graded from 0 to 3 as follows: 0, no flow; 1, intermittent flow; 2, sluggish flow; 3, continuous flow. The secondary outcome was a composite adverse outcome within 30 days after surgery. Cytokines and endothelial biomarkers were measured in all patients at different time points. An intention-to-treat analysis was performed. RESULTS: From October 2019 to November 2022, the study included 70 patients. Two patients were excluded from the Oxiris group: one patient did not undergo surgery, and one procedure was performed under deep hypothermia. The microvascular flow index did not differ between groups on day 1 from baseline: difference (95% CI) Oxiris minus standard at -0.17 (-0.44 to 0.10); P = 0.2. The occurrence of a composite adverse outcome did not significantly differ between groups (14 [42%] for the Oxiris group vs. 12 [35%] for the standard group; P = 0.7). The overall variation in cytokines and angiopoietins did not significantly differ between groups. CONCLUSIONS: In patients scheduled for a cardiac surgery with prolonged CPB, the authors could not demonstrate the benefit on microcirculation and major cardiovascular events.
引用
- Abou-Arab O, Huette P, Ibrahima A, et al. Cytokine Hemoadsorption versus Standard Care in Cardiac Surgery Using the Oxiris Membrane: The OXICARD Single-center Randomized Trial. Anesthesiology. 2025. PMID: 39841886. doi:10.1097/ALN.0000000000005376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。